Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

被引:41
|
作者
Paudyal, Pramila [1 ,2 ]
Paudyal, Bishnuhari [1 ,2 ]
Hanaoka, Hirofumi
Oriuchi, Noboru [1 ,2 ]
Iida, Yashuhiko
Yoshioka, Hiroki [1 ,2 ]
Tominaga, Hideyuki [1 ,2 ]
Watanabe, Satoshi [3 ]
Watanabe, Shigeki [3 ]
Ishioka, Noriko S. [3 ]
Endo, Keigo [1 ,2 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词
PHASE-II TRIAL; BREAST-CANCER; ANTIBODY; GEMCITABINE; CISPLATIN; MICE;
D O I
10.1111/j.1349-7006.2010.01480.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
下载
收藏
页码:1045 / 1050
页数:6
相关论文
共 50 条
  • [1] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Hirsch, FR
    Langer, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82
  • [2] ImmunoPET imaging of HER2 expression in ovarian cancer using 64Cu-labeled pertuzumab
    Jiang, Dawei
    Im, Hyung-Jun
    England, Christopher
    Ehlerding, Emily
    Graves, Stephen
    Barnhart, Todd
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [3] 64Cu-labeled panitumumab for PET imaging of EGFR plus non-small cell lung cancer: Subcutaneous and metastatic mouse models
    Wuest, Frank
    Sarrami, Nasim
    Wuest, Melinda
    Paiva, Igor
    Leier, Samantha
    Lavasanifar, Afsaneh
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S188 - S188
  • [4] PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-labeled Ramucirumab
    Luo, Haiming
    England, Christopher
    Sun, Haiyan
    Graves, Stephen
    Nickles, Robert
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab
    Luo, Haiming
    England, Christopher G.
    Graves, Stephen A.
    Sun, Haiyan
    Liu, Glenn
    Nickles, Robert I.
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) : 285 - 290
  • [6] 64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors
    Cheng, Zhen
    De Jesus, Omayra Padilla
    Kramer, Daniel J.
    De, Abhijit
    Webster, Jack M.
    Gheysens, Olivier
    Levi, Jelena
    Namavari, Mohammad
    Wang, Sen
    Park, Jinha Mark
    Zhang, Rong
    Liu, Hongguang
    Lee, Brian
    Syud, Faisal A.
    Gambhir, Sanjiv Sam
    MOLECULAR IMAGING AND BIOLOGY, 2010, 12 (03) : 316 - 324
  • [7] 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents
    Kwon, Luke Yongkyu
    Scollard, Deborah A.
    Reilly, Raymond M.
    MOLECULAR PHARMACEUTICS, 2017, 14 (02) : 492 - 501
  • [8] 64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors
    Zhen Cheng
    Omayra Padilla De Jesus
    Daniel J. Kramer
    Abhijit De
    Jack M. Webster
    Olivier Gheysens
    Jelena Levi
    Mohammad Namavari
    Sen Wang
    Jinha Mark Park
    Rong Zhang
    Hongguang Liu
    Brian Lee
    Faisal A. Syud
    Sanjiv Sam Gambhir
    Molecular Imaging and Biology, 2010, 12 : 316 - 324
  • [9] EGFR and HER2/NEU in gefitinib chemotherapy for non-small cell lung cancer
    Yoo, J.
    HISTOPATHOLOGY, 2008, 53 : 406 - 406
  • [10] Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody
    Dearling, Jason L. J.
    Voss, Stephan D.
    Dunning, Patricia
    Snay, Erin
    Fahey, Frederic
    Smith, Suzanne V.
    Huston, James S.
    Meares, Claude F.
    Treves, S. Ted
    Packard, Alan B.
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (01) : 29 - 38